Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature

• Published in: Leukemia research Vol. 39; no. 7; pp. 739 - 748
• Main Authors: Börschel, Niklas, Schwöppe, Christian, Zerbst, Caroline, Angenendt, Linus, Kessler, Torsten, Klapper, Wolfram, Giovannoni, Leonardo, Elia, Giuliano, Neri, Dario, Berdel, Wolfgang E, Mesters, Rolf M, Schliemann, Christoph
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-07-2015
• Subjects: Animals; Antibodies, Monoclonal, Murine-Derived - therapeutic use; Antineoplastic Agents - therapeutic use; Female; Hematology, Oncology and Palliative Medicine; Immunocytokine; Interleukin-2; Interleukin-2 - pharmacology; Interleukin-2 - therapeutic use; Lymphoma, Mantle-Cell - drug therapy; Mantle cell lymphoma; Mice; Mice, SCID; Neovascularization, Pathologic - prevention & control; Rituximab; Vascular targeting; Immunocytokine; Vascular targeting; Rituximab; Interleukin-2; Mantle cell lymphoma
• ISSN: 0145-2126; 1873-5835
• DOI: 10.1016/j.leukres.2015.04.005

Highlights • L19-IL2 is a fully human immunocytokine that targets EDB-Fn positive blood vessels. • L19-IL2 efficiently homes to angiogenic vessels in mantle cell lymphomas (MCL) in mice. • The antibody-mediated accumulation of IL-2 recruits immune cells to the lymphoma tissue. • L19-IL2 strongly potentiates the activity of anti-CD20 immunotherapy against MCL xenografts. • EDB-Fn is expressed in the vasculature of human MCL samples.